KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Efficacy of Esaxerenone Plus a Renin-Angiotensin System Inhibitor or Calcium Channel Blocker for Nocturnal Hypertension: A Post Hoc Analysis.

Kazuomi Kario, Sadayoshi Ito, Hiroshi Itoh, Hiromi Rakugi, Yasuyuki Okuda, Satoru Yamakawa

Am J Hypertens 38(8) 605-611

PMID40178088
PMCIDPMC12260155
DOI10.1093/ajh/hpaf048
发表日期2025-04-03
入排依据:未发现恶性肿瘤人群证据。
已检查 3 张 PubMed Figure,均未识别为 KM 图:Graphical Abstract:AI 判定为 other;Figure 1:AI 判定为 other;Figure 2:AI 判定为 other。
摘要

摘要

BACKGROUND: Nocturnal blood pressure (BP) is superior to daytime BP in predicting cardiovascular mortality. It is of clinical relevance to evaluate the effect of esaxerenone combination therapy on nighttime BP in patients with uncontrolled hypertension. METHODS: A post hoc analysis of a multicenter, open-label, phase 3 study evaluated the nighttime BP-lowering effects of esaxerenone as monotherapy or in combination with a calcium channel blocker (CCB) or renin-angiotensin system inhibitor (RASi) in Japanese patients with uncontrolled hypertension. In addition, the effect on N-terminal pro B-type natriuretic peptide (NT-proBNP), a known biomarker of cardiovascular disease prognosis, was evaluated. RESULTS: In total, 270 patients were included in this analysis (172, 49, and 49 patients in the monotherapy, CCB, and RASi groups, respectively). The 24-hour ambulatory systolic BP reduction from baseline was - 10.0, - 6.0, and - 17.0 mm Hg in the monotherapy, CCB, and RASi groups, respectively. Nighttime systolic BP decreased significantly from baseline to week 28 in all groups (P < 0.001 each); the RASi group showed the greatest change (- 20.6 mm Hg). NT-proBNP decreased significantly in all three treatment groups. CONCLUSIONS: Esaxerenone when used in combination with a CCB or RASi, but especially when used in combination with a RASi, may be a useful treatment option for patients with uncontrolled hypertension to control nocturnal BP.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Graphical AbstractGraphical Abstract
非 KM Figure
Figure 1Figure 1. LS mean change from baseline to week 28 in SBP. * P < 0.01 and ** P < 0.001 vs. baseline BP, blood pressure; CCB, calcium channel blocker; LS, least squares; RASi, renin–angiotensin system inhibitor; SBP, systolic blood pressure
非 KM Figure
Figure 2Figure 2. Geometric least squares mean percentage change from baseline to week 28 in NT-proBNP level. * P < 0.01 and ** P < 0.001 vs. baseline CCB, calcium channel blocker; NT-proBNP, N-terminal pro B-type natriuretic peptide; RASi, renin–angiotensin system inhibitor
非 KM Figure